BLTE Live signals | Maximize Profits with Getagraph.com

BUY 101034 min ago

@ $47.00

Issued: 13 Feb 2024 @ 09:30

Return: -21.28%

Previous signal: Feb 9 - 09:43

Previous signal: Sell

Return: 0.90 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 14:24):

Stats
Today's Volume	17 228.00
Average Volume	50 908.00
Market Cap	1.10B
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.340 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-31.09
ATR14	$0.0780 (0.21%)

Volume Correlation

Long: -0.41 (neutral)

Short: 0.48 (neutral)

Signal:(60.318) Neutral

Belite Bio, Inc Correlation

10 Most Positive Correlations
VLCN	0.958
HIBB	0.957
IART	0.953
JRJC	0.945
VBFC	0.935
EMKR	0.935
IEP	0.934
IVAC	0.929
MLAB	0.926
GOGL	0.924

10 Most Negative Correlations
SMCI	-0.957
OPRA	-0.953
VIRI	-0.951
NVDA	-0.949
HGBL	-0.949
TZPS	-0.944
RXST	-0.943
AIB	-0.942
FRBN	-0.941
MLAI	-0.938

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Belite Bio, Inc Correlation - Currency/Commodity

-0.18
( neutral )

-0.55
( weak negative )

-0.47
( neutral )

0.22
( neutral )

0.25
( neutral )

0.91
( very strong )

Belite Bio, Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-399 000 (0.00 %)
EPS:	$-1.190

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.250

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.400

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.260

Financial Reports:

No articles found.

Belite Bio, Inc

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.